Related Experiment Video
Updated: Feb 13, 2026
Systematic Assessment of Mammalian Skull Specimens for Dental and Temporomandibular Joint Pathology
Published on: August 22, 2022
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of
Erik Lindström1, Biljana Rizoska2, Karin Tunblad1
1Medivir AB, Box 1086, 141 22, Huddinge, Sweden.
Background:
MIV-711 is a highly potent and selective cathepsin K inhibitor. The current article summarizes the therapeutic effects of MIV-711 on joint pathology in rabbits subjected to anterior cruciate ligament transection (ACLT), and the prophylactic effects on joint pathology in dogs subjected to partial medial meniscectomy, two surgical models of osteoarthritis (OA).
Methods:
Starting 1 week after surgery, rabbits were dosed daily via oral gavage with either MIV-711 or vehicle (n = 7/group) for 7 weeks. The four treatment groups were: (1) sham + vehicle; (2) ACLT + vehicle; (3) ACLT + MIV-711, 30 µmol/kg and (4) ACLT + MIV-711, 100 µmol/kg. Subchondral bone and articular cartilage structures were assessed by µCT, histomorphometry, and scoring. Dogs subjected to partial medial meniscectomy received either MIV-711 (30 µmol/kg) or vehicle (n = 15/group) via oral gavage once daily, starting 1 day before meniscectomy, for 28 days. Cartilage degradation was assessed at the macroscopic and microscopic levels. The exposures of MIV-711 were assessed in both studies and biomarkers reflecting bone resorption (HP-1 in rabbits, CTX-I in dogs) and cartilage degradation (CTX-II) were measured.
Results:
In ACLT rabbits, MIV-711 decreased HP-1 levels by up to 72% (p < 0.001) and CTX-II levels by up to 74% (p < 0.001) compared to ACLT vehicle controls. ACLT surgery significantly reduced the total thickness of the subchondral bone plate and reduced trabecular bone volume in the femur and tibia. These effects were reversed by MIV-711. ACLT resulted in cartilage thickening, which was attenuated by MIV-711. MIV-711 did not affect osteophyte formation or Mankin scores. In dogs, MIV-711 reduced CTX-I and CTX-II levels by 86% (p < 0.001) and 80% (p < 0.001), respectively. Synovial CTX-II levels were reduced by 55-57% (p < 0.001) compared to baseline. MIV-711-treated animals had 25-37% lower macroscopic scores in the femur condyles and 13-33% lower macroscopic scores in the tibial plateaus.
Conclusions:
MIV-711 prevents subchondral bone loss and partially attenuates cartilage pathology in two animal models of OA. These beneficial effects of MIV-711 on joint pathology are observed in conjunction with decreases in bone and cartilage biomarkers that have been shown to be clinically attainable in human. The data support the further development of MIV-711 for the treatment of OA.
Insights
MIV-711, a cathepsin K inhibitor, demonstrated therapeutic effects in osteoarthritis (OA) animal models. It prevented bone loss and reduced cartilage damage, supporting its potential for OA treatment.
Area of Science:
- Orthopedics
- Pharmacology
- Biochemistry
Background:
- Osteoarthritis (OA) is a degenerative joint disease.
- Cathepsin K is implicated in OA pathogenesis.
- MIV-711 is a selective cathepsin K inhibitor.
Purpose of the Study:
- To evaluate the therapeutic effects of MIV-711 on joint pathology in rabbit and dog OA models.
- To assess the prophylactic effects of MIV-711 in a canine OA model.
Main Methods:
- Rabbits underwent anterior cruciate ligament transection (ACLT) and were treated with MIV-711 or vehicle.
- Dogs underwent partial medial meniscectomy and were treated with MIV-711 or vehicle.
- Joint pathology was assessed using micro-computed tomography (µCT), histomorphometry, and macroscopic/microscopic scoring.
- Biomarkers for bone resorption (HP-1, CTX-I) and cartilage degradation (CTX-II) were measured.
Main Results:
- MIV-711 significantly reduced bone resorption and cartilage degradation biomarkers in both rabbit and dog models.
- In rabbits, MIV-711 reversed subchondral bone loss and attenuated cartilage thickening.
- In dogs, MIV-711 decreased macroscopic and microscopic cartilage degradation scores.
Conclusions:
- MIV-711 effectively prevents subchondral bone loss and partially attenuates cartilage pathology in OA animal models.
- The observed effects correlate with clinically attainable biomarker reductions.
- These findings support the further development of MIV-711 for osteoarthritis treatment.
Related Concept Videos
02:42Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
01:16Structural Joints: Synovial Joints
01:03Structural Joints: Fibrous Joints
Suture
All the bones of the skull, except for the mandible, are joined to each other by a fibrous joint called a suture. The fibrous connective tissue found at a suture strongly unites the adjacent skull bones and thus helps to protect the brain and form the face. In...
01:17Structural Joints: Cartilaginous Joints
There are two types of cartilaginous joints:
Synchondrosis
A synchondrosis ("joined by cartilage") is a cartilaginous joint where bones are connected by hyaline cartilage. Synchondrosis may be temporary...
01:26Joints
Structural joint classifications are based on the material that makes up the joint as well as whether or not the joint contains a space between the bones. Joints are structurally classified as fibrous, cartilaginous, or synovial.
Fibrous Joints Are Immovable
The bones of a...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...